Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 31;14(8):e28624.
doi: 10.7759/cureus.28624. eCollection 2022 Aug.

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

Lucy Kerr  1 , Fernando Baldi  2 , Raysildo Lobo  3 , Washington Luiz Assagra  4 , Fernando Carlos Proença  5 , Juan J Chamie  6 , Jennifer A Hibberd  7 , Pierre Kory  8 , Flavio A Cadegiani  9   10
Affiliations

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

Lucy Kerr et al. Cureus. .

Abstract

Background We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose-response effect. Methods This exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2 mg/kg/day for two consecutive days, every 15 days, for 150 days. Regularity definitions were as follows: regular users had 180 mg or more of ivermectin and irregular users had up to 60 mg, in total, throughout the program. Comparisons were made between non-users (subjects who did not use ivermectin), and regular and irregular users after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and the risk of dying from COVID-19. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality rates. Results Among 223,128 subjects from the city of Itajaí, 159,560 were 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg) and 8,325 (7.3%) used regularly (more than 180 mg). The remaining 71,548 participants were not included in the analysis. COVID-19 infection rate was 49% lower for regular users (3.40%) than non-users (6.64%) (risk rate (RR): 0.51; 95% CI: 0.45-0.58; p < 0.0001), and 25% lower than irregular users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p < 0.0001). The infection rate was 32% lower for irregular users than non-users (RR: 0.68; 95% CI: 0.64-0.73; p < 0.0001). Among COVID-19 participants, regularusers were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users. After PSM, the matched analysis contained 283 subjects in each group of non-users and regular users, between regular users and irregular users, and 1,542 subjects between non-users and irregular users. The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p < 0.0001), and by 29% among irregular users compared to non-users (RR: 0.781; 95% CI: 0.49-1.05; p = 0.099). Mortality rate was 92% lower in regular users than non-users (RR: 0.08; 95% CI: 0.02-0.35; p = 0.0008) and 84% lower than irregular users (RR: 0.16; 95% CI: 0.04-0.71; p = 0.016), while irregular users had a 37% lower mortality rate reduction than non-users (RR: 0.67; 95% CI: 0.40-0.99; p = 0.049). Risk of dying from COVID-19 was 86% lower among regular users than non-users (RR: 0.14; 95% CI: 0.03-0.57; p = 0.006), and 72% lower than irregular users (RR: 0.28; 95% CI: 0.07-1.18; p = 0.083), while irregular users had a 51% reduction compared to non-users (RR: 0.49; 95% CI: 0.32-0.76; p = 0.001). Conclusion Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.

Keywords: coronavirus; coronavirus disease 2019; covid-19; ivermectin; ivermectin (ivm); prevention; prophylaxis; rtpcr-sars-cov-2; sars-cov-2.

PubMed Disclaimer

Conflict of interest statement

Lucy Kerris is a paid consultant for both Vitamedic, an ivermectin manufacturer, and is co-founder, as well as acting as a paid consultant, for Médicos Pela Vida (MPV), an organization that promotes ivermectin as a treatment for COVID-19 and discourages COVID-19 vaccination. Flavio A. Cadegiani was a paid consultant (USD 1,600.00) for Vitamedic, an ivermectin manufacturer. Dr. Cadegiani is a founding member of the Front Line COVID-19 Critical Care Alliance (FLCCC), an organization that promotes ivermectin as a treatment for COVID-19. Pierre Kory is the President and Chief Medical Officer of the Front Line COVID-19 Critical Care Alliance (FLCCC), an organization that promotes ivermectin as a treatment for COVID-19 and discourages COVID-19 vaccination. Dr. Kory reports receiving payments from FLCCC. In February of 2022, Dr. Kory opened a private telehealth fee-based service to evaluate and treat patients with acute COVID, long-haul COVID, and post-vaccination syndromes. Dr. Kory expresses personal points of view against COVID-19 vaccination. Jennifer A. Hibberd is a co-founder of the Canadian Covid Care Alliance and World Council for Health, both of which discourage vaccination and encourage ivermectin as a treatment for COVID-19. Juan J. Chamie-Quintero is a contributor to the Front Line COVID-19 Critical Care Alliance (FLCCC), lists the FLCCC as his employer on his LinkedIn page, and expresses personal points of view against COVID-19 vaccination.

Figures

Figure 1
Figure 1. Illustrative study guide
Figure 2
Figure 2. Impact of ivermectin use on infection rates during the overall, first half, and second half of the program in non-users, regular users, and irregular users
Figure 3
Figure 3. Hospitalization rates for the overall population in post-matched groups
RR = risk ratio; CI = confidence interval.
Figure 4
Figure 4. Mortality rates in the post-matched, overall population, and subpopulation groups
RR = risk ratio; CI = confidence interval.
Figure 5
Figure 5. Risk of dying from COVID-19 among ivermectin non-users, regular users, and irregular users
RR = risk ratio; CI = confidence interval.
Figure 6
Figure 6. COVID-19 infection, hospitalization, mortality rates, and risk of dying from COVID-19 across different patterns of ivermectin use
Figure 7
Figure 7. Hospitalization rates before matching in ivermectin non-users, irregular users, and regular users
RR = risk ratio; CI = confidence interval.
Figure 8
Figure 8. Pre-matching mortality rates in ivermectin non-users, irregular users, and regular users
RR = risk ratio; CI = confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. J Antimicrob Chemother. 2012;67:1884–1894. - PMC - PubMed
    1. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Biochem J. 2012;443:851–856. - PMC - PubMed
    1. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. Crump A. J Antibiot (Tokyo) 2017;70:495–505. - PubMed
    1. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. Heidary F, Gharebaghi R. J Antibiot (Tokyo) 2020;73:593–602. - PMC - PubMed
    1. Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. Li N, Zhao L, Zhan X. J Cell Physiol. 2021;236:2959–2975. - PMC - PubMed

LinkOut - more resources